Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$0.43
−$0.27 · -38.57%
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Latest quote
$0.43
−$0.27 · -38.57%
After-hours
$0.416
−$0.014 · -3.26%
Oct 8, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Day range
Current $0.43
52-week range
Current $0.43
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
54
Fair Value
Sentiment
58
Mixed
Risk
71
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Day range
Current $0.43
52-week range
Current $0.43
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 36.31M USD | 34.87M USD | 24.09M USD | 4.35M USD | 228.43K USD |
| Cost of goods sold | 24.38M USD | 24.2M USD | 15.75M USD | 2.65M USD | 117.83K USD |
| Gross profit | 11.92M USD | 10.67M USD | 8.34M USD | 1.7M USD | 110.6K USD |
| Research and development | 604.31K USD | 933.9K USD | 1.86M USD | 811.86K USD | 672.21K USD |
| Selling, general, and administrative | 19.63M USD | 14.94M USD | 10.83M USD | 9.48M USD | 1.87M USD |
| Operating expenses | 16.4M USD | 16.48M USD | 13.12M USD | 10.37M USD | 2.55M USD |
| Interest income | 280.9K USD | 496K USD | 811.97K USD | 518.65K USD | — |
| Interest expense | — | 8.77K USD | 137.31K USD | 39.41K USD | 328.82K USD |
| Depreciation and amortization | 332.07K USD | 223.53K USD | 149.15K USD | 25.16K USD | 12.74K USD |
| Operating income | −4.48M USD | −5.81M USD | −4.79M USD | −8.67M USD | −2.44M USD |
| Net income | −5.98M USD | −5.13M USD | −4.51M USD | −26.74M USD | −12.44M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 1, 2026 | 1:10 | — | — |
Stock split | Aug 8, 2024 | 1:20 | — | — |
Stock split | Apr 17, 2024 | 1:100 | — | — |
Stock split | Feb 9, 2022 | 1:200 | — | — |
Stock split | Apr 6, 2020 | 1:20 | — | — |
Stock split | Feb 1, 2019 | 1:20 | — | — |
Effective Jun 1, 2026
1:10
Effective Aug 8, 2024
1:20
Effective Apr 17, 2024
1:100
Effective Feb 9, 2022
1:200
Effective Apr 6, 2020
1:20
Effective Feb 1, 2019
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
